Detection of Bone Metastases by ⁶⁸Ga-DOTA-SSAs and ¹⁸F-FDG PET/CT: A Two-Center Head-to-Head Study of Gastroenteropancreatic Neuroendocrine Neoplasms

Table 1

Patient characteristics (n = 74).

Basics	Total	G1 + G2	NET G3	NEC	P
N (%)	74	50	12	12
Age at image (mean ± SD)	55.93 ± 11.025	55.66 ± 10.817	51.58 ± 8.028	61.42 ± 12.930	0.086
Sex, M/F (%)	47/27 (63.51/36.49)	32/18 (64.00/36.00)	8/4 (66.67/33.33)	7/5 (58.33/41.67)	0.905
Primary sites (n, %)
Stomach	6 (8.11)	3 (6)	1 (8.33)	2 (16.67)	0.546
Intestine	34 (45.95)	28 (56)a	4 (33.33)b	2 (16.67)c	0.028
Pancreas	26 (35.14)	17 (34)	4 (33.33)	5 (41.67)	0.933
Esophagus	3 (4.05)	1 (2)		2 (16.67)	0.133
Biliary tract	2 (2.70)		1 (8.33)	1 (8.33)	0.102
Unknown primary origin	3 (4.05)	1 (2)	2 (16.67)		0.133
Other extra-osseous metastases (n, %)
Liver metastases	69 (93.24)	48 (96)	11 (91.67)	10 (83.33)	0.482
Lymph node metastases	50 (67.57)	36 (72)	5 (41.67)	9 (75)	0.134
Symptoms	15 (20.27)	7 (14)	3 (25)	5 (41.67)	0.073
CT findings (n, %)
Osteogenesis	41 (55.41)	34 (68)a	5 (41.67)b	2 (16.67)c	0.003
Osteolysis	18 (24.32)	9 (18)	5 (4.05)	4 (33.33)	0.245
No change	15 (20.27)	7 (14)b	2 (16.67)b	6 (50)a	0.026

CT, computed tomography; M/F, male/female; _a,b, and _c (where _a>_b>_c) mark statistically significant differences between each group.